6 unknown, 4 completed, 2 active not recruiting, 1 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Unknown 6, Completed 4, Active not recruiting 2, Terminated 1 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis Aripiprazole, Paliperidone - Schizophrenia, Treatment-resistant Schizophrenia | Phase 4 | Unknown | Consorcio Centro de Investigación Biomédica en Red (CIBER) | 244 | 2023-11-01 | 2023-09-29 |
| A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities Saroglitazar - NAFLD, Obesity | Phase 4 | Unknown | Zydus Lifesciences Limited | 1500 | 2023-07-20 | 2024-02-07 |
| Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD Berberine plus lifestyle intervention, Placebo plus lifestyle intervention - Obesity, Obesity, Abdominal | Phase 4 | Completed | China National Center for Cardiovascular Diseases | 337 | 2023-07-06 | 2025-01-29 |
| Semaglutide vs Sitagliptin Semaglutide Treatment, Sitagliptin 100mg - Liver Transplant; Complications, Diabetes Mellitus | Phase 4 | Active not recruiting | University Health Network, Toronto | 58 | 2022-10-26 | 2026-10-14 |
| Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients Empagliflozin 10 MG, Placebo pills - Chronic Hepatitis b, NAFLD | Phase 4 | Active not recruiting | The University of Hong Kong | 106 | 2022-01-02 | 2026-01-30 |
| Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin - Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | Phase 4 | Unknown | Getz Pharma | 123 | 2021-09-15 | 2022-03-18 |
| Probiotic Supplementation IN NAFLD Patients Control Test - NAFLD | Phase 4 | Completed | Ain Shams University | 50 | 2021-09-12 | 2023-10-10 |
| Follow-up of NAFLD Patients With MRI-PDFF Empagliflozin 25 MG, Ursodeoxycholic acid, Pentoxifylline 400 MG - Diabetes Type 2, NAFLD | Phase 4 | Completed | Asmaa Abdelfattah Elsayed | 80 | 2020-12-01 | 2022-12-20 |
| The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) Gut microbiome transplantation - NAFLD | Phase 4 | Unknown | Leiden University Medical Center | 20 | 2019-12-10 | 2020-07-09 |
| Effect of Obesity on Proton Pump Inhibitors Lansoprazole, Pantoprazole, Midazolam - Pediatric Obesity, NAFLD | Phase 4 | Completed | Children's Mercy Hospital Kansas City | 76 | 2018-07-03 | 2026-06-04 |
| The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Empagliflozin - Type2 Diabetes, NAFLD | Phase 4 | Unknown | University of Malaya | 25 | 2016-11-01 | 2017-05-31 |
| Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Metadoxine - NAFLD, Pre-diabetes | Phase 4 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 100 | 2016-01-01 | 2019-01-31 |
| Rifaximin in Fatty Liver Disease Rifaximin - Nonalcoholic Fatty Liver Disease, NAFLD | Phase 4 | Terminated | Imperial College London | 15 | 2011-05-01 | 2020-10-28 |
Non-alcoholic Fatty Liver Disease (13) · Diabetes Mellitus, Type 2 (3) · Diabetes Mellitus (2) · Obesity (2) · Dyslipidemias (1) · Fibrosis (1) · Gastroesophageal Reflux (1) · Glucose Intolerance (1) · Hepatitis B, Chronic (1) · Inflammation (1) · Insulin Resistance (1) · Lipid Metabolism Disorders (1) · Liver Cirrhosis (1) · Metabolic Syndrome (1) · Obesity, Abdominal (1)
Digestive System Diseases (13) · Fatty Liver (13) · Liver Diseases (13) · Nutritional and Metabolic Diseases (9) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7) · Endocrine System Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Body Weight (3) · Diabetes Mellitus (3) · Nutrition Disorders (3) · Overnutrition (3) · Overweight (3) · Signs and Symptoms (3) · Hyperinsulinism (2)
empagliflozin (4) · Aripiprazole (1) · Berberine (1) · Fecal Microbiota Transplantation (1) · Lansoprazole (1) · Midazolam (1) · Paliperidone Palmitate (1) · Pantoprazole (1) · Pentoxifylline (1) · Pioglitazone (1) · Rifaximin (1) · Sitagliptin Phosphate (1) · Ursodeoxycholic Acid (1) · metadoxine (1) · saroglitazar (1)
Ain Shams University (1) · Asmaa Abdelfattah Elsayed (1) · Children's Mercy Hospital Kansas City (1) · China National Center for Cardiovascular Diseases (1) · Consorcio Centro de Investigación Biomédica en Red (CIBER) (1) · Getz Pharma (1) · Imperial College London (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Leiden University Medical Center (1) · The University of Hong Kong (1) · University Health Network, Toronto (1) · University of Malaya (1) · Zydus Lifesciences Limited (1)
Egypt (2) · Canada (1) · China (1) · Hong Kong (1) · India (1) · Malaysia (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · United Kingdom (1) · United States (1)
Aldo Torre, MD MSci (1) · Asmaa A Elsayed, PhD (1) · Dr. Deven Parmar, MD,FCP (1) · Haibo Zhang, MD (1) · Javier Labad Arias, MD, PhD (1) · Jeremy FL Cobbold, PhD (1) · Jing Li, PhD (1) · Ka Shing Cheung, MD, MPH (1) · Kathryn Kyler, MD, MS (1) · Mamatha Bhat, MD (1) · Mark R Thursz, MD (1) · Shireene R Vethakkan, MD (1)
PMID 30684076, PMID 39379797, PMID 40755230, PMID 41543854
K23DK115827 (1)